KRYSTAL BIOTECH Receives FDA Approval for Topical Gene Therapy to Treat Rare Skin Disorder

Trending News ☀️

Krystal Biotech ($NASDAQ:KRYS), Inc., a gene therapy company, recently received approval from the US Food and Drug Administration (FDA) for its topical gene therapy to treat a rare skin disorder. This marks a major milestone for Krystal Biotech, a publicly-traded company based in Pittsburgh, Pennsylvania that specializes in developing innovative gene therapies for a variety of serious medical conditions. Krystal Biotech is dedicated to developing treatments that are both safe and effective. Their breakthrough gene therapy relies on a powerful vector called SkintifecTM that can be delivered directly to the site of the affected skin tissue. Once there, the therapy works by delivering healthy copies of a gene that is mutated or missing in the patient’s body.

This helps to restore the skin’s ability to repair itself, resulting in rapid visible improvements. It is also a major achievement for the company’s research and development team, whose tireless efforts have resulted in this groundbreaking treatment. Going forward, Krystal Biotech will continue to strive towards developing therapies that provide long-term relief to those who need it most.

Market Price

This groundbreaking approval marks the first of its kind for the company, and has seen a surge in its stock price. KRYSTAL BIOTECH opened at $88.6 and closed at $96.1 on the day of the announcement, representing a 9.8% increase from the previous closing price of 87.4. The gene therapy will provide an effective treatment option for those affected by the rare skin disorder, offering them relief from pain and discomfort. This revolutionary move from KRYSTAL BIOTECH is certain to have a lasting impact on the medical industry, and marks an exciting step forward for the future of gene therapy. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Krystal Biotech. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Krystal Biotech. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Krystal Biotech. More…

Key Ratios Snapshot

Some of the financial key ratios for Krystal Biotech are shown below. More…

Analysis

At GoodWhale, we analyze the financial and business aspects of investments to provide an accurate assessment of a company’s wellbeing. We recently took a look at KRYSTAL BIOTECH to get a better sense of how they stack up, and based on our Risk Rating, we found that they are classified as a medium risk investment. We have also detected 3 risk warnings in their income sheet, balance sheet, and cashflow statement. To get more information about these warning signs, register with us and we’ll be happy to provide you with the details. More…

Peers

The company is among several biopharmaceutical companies in the industry, including GT Biopharma Inc, Jounce Therapeutics Inc, and CytomX Therapeutics Inc, that are focused on developing innovative treatments for serious diseases.

– GT Biopharma Inc ($NASDAQ:GTBP)

GBT Biopharma Inc is a biopharmaceutical company that develops and commercializes treatments for cancer and other diseases. The company has a market cap of 35.49M as of 2022, which is relatively low compared to the market cap of many larger biopharmaceutical companies. Additionally, the company has a negative Return on Equity (ROE) of -132.59%, which indicates that the company is not able to generate profits from its investments and is likely not a good investment option.

– Jounce Therapeutics Inc ($NASDAQ:JNCE)

Jounce Therapeutics Inc is a biopharmaceutical company focused on developing therapies to improve the lives of people with cancer. The company currently has a market cap of 40.84M, making it relatively small when compared to other biotechnology companies in the sector. In terms of Return on Equity, Jounce Therapeutics Inc has a negative ROE of -57.85%. This reflects the company’s inability to generate profits and its need for additional capital to finance its operations. Despite these challenges, the company remains committed to its mission of developing innovative treatments for cancer patients.

– CytomX Therapeutics Inc ($NASDAQ:CTMX)

CytomX Therapeutics Inc is a biopharmaceutical company that develops innovative therapeutics for oncology and other diseases. The company’s market cap as of 2022 is 102.43M, indicating that the company has a moderate amount of liquidity and is in a good position to invest in its operations. However, its Return on Equity (ROE) of -160.27% suggests that the company has not been able to generate profits from its investments and is struggling to achieve positive earnings. This could be due to the high cost of research and development, or a lack of focus on core business activities.

Summary

Investors reacted positively to the news and the stock price of Krystal Biotech experienced an increase. This is a momentous event for the company as it will now have access to a new market and could potentially increase revenue. Investors should pay close attention to the progress of Krystal Biotech as its success could be a great opportunity for returns. With the FDA approval, their new product is likely to become a successful medication and could result in a rise in stock prices.

It is also worth noting that this approval could open the door to potential collaborations with larger pharmaceutical companies. Thus, investors may want to consider buying or holding onto Krystal Biotech stock as this could lead to long-term growth.